Danielle Bucco

Opdivo had promising response rates in a recent trial testing the treatment in patients with relapsed or refractory Hodgkin lymphoma.

Peter Martin, M.D., discusses the evolving field of mantle cell lymphoma treatment.

Arjun V. Balar, M.D., discusses Keytruda's impact on the treatment of urothelial carcinoma.

Patients who choose not to have their thyroid cancer treated often have feelings of anxiety and isolation, and are at a risk of disengaging from the health care system because they might not feel supported.

Pap smears are an important test that can detect cervical cancer, but unfortunately many women are not up to date with their testing.

Minimally invasive approaches are being explored to lower associated adverse events and, overall, improve patient outcomes for patients with head and neck cancer.

Shana Wingo, M.D., discussed advancements being made in the field of surgery for patients with gynecologic cancers.

While other tumor types have seen extraordinary progress with immunotherapy agents such as Opdivo (nivolumab) and Yervoy (ipilimumab), they have not yet shown similar success in the treatment of prostate cancer. Padmanee Sharma, M.D., Ph.D., weighs in.

Mutations might be the answer as to why sidedness has an effect on colorectal cancer outcomes.

A debate among health care providers has ensued over the cardiotoxicity risk that is associated with anthracycline regimens for patients with breast cancer. Sara A. Hurvitz, M.D., weighs in.

Adam M. Brufsky, M.D., Ph.D., discusses bone-targeted agents in breast cancer, and what we can expect for the future of this kind of therapy.

Sara Hurvitz, M.D. talks about recent and upcoming advancements in the treatment of HER2-positive breast cancer

John E. Mullinax, M.D., discusses a chemotherapy strategy that may be able to save the limbs of some patients with sarcoma.

Hormonal maintenance therapy may be able to improve PFS rates for some patients with ovarian cancer, according to a recent study.

Leo I. Gordon, M.D., discusses an exciting new trial for patients with non-Hodgkin lymphoma.

Managing brain metastases has become a difficult problem in patients with breast cancer.

A phase 2 trial is showing that GPX-150 is promising for patients with soft tissue sarcoma.

Checkpoint inhibitors drastically changed the treatment landscape of urothelial carcinoma, and more changes are on the way.

Researchers at the University of Michigan are hoping to improve the survival rates for laryngeal cancer.

Sutent treatment breaks seem to have no effect on clinical efficacy for patients with renal cell carcinoma.

H. Jack West, M.D., explains how to best optimize the treatment of EGFR-mutated non-small cell lung cancer by using TKIs.

Adding Ibrance to Imbruvica may be a promising treatment strategy for patients with mantle cell lymphoma, according to a recent study.

Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.

The best chemotherapy strategy (IP versus IV) for patients with ovarian cancer is still being debated. Franco M. Muggia, M.D., weighs in.

CURE spoke with David Albala, M.D., about the impact robotic surgery has had on patients with prostae cancer.

David F. McDermott, M.D., is optimistic about combination regimens shaping the treatment landscape for renal cell carcinoma.

Imbruvica (ibrutinib) improved survival for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL), according to study results that were recently presented.

Chemotherapy agents such as docetaxel will remain a crucial part of treating patients with advanced prostate cancer, says William Oh, M.D.